The Hsp90 chaperone complex as a novel target for cancer therapy.
about
Chaperoning checkpoint kinase 1 (Chk1), an Hsp90 client, with purified chaperonesSuppression of the mTOR-raptor signaling pathway by the inhibitor of heat shock protein 90 geldanamycinSecreted heat shock protein 90alpha induces colorectal cancer cell invasion through CD91/LRP-1 and NF-kappaB-mediated integrin alphaV expressionThe heat shock protein 90 of Plasmodium falciparum and antimalarial activity of its inhibitor, geldanamycinInhibition of Hsp90 acts synergistically with topoisomerase II poisons to increase the apoptotic killing of cells due to an increase in topoisomerase II mediated DNA damageGRP94: An HSP90-like protein specialized for protein folding and quality control in the endoplasmic reticulumMagnetic resonance spectroscopy detectable metabolomic fingerprint of response to antineoplastic treatmentChemotherapeutic potential of 17-AAG against cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensisMultifaceted intervention by the Hsp90 inhibitor ganetespib (STA-9090) in cancer cells with activated JAK/STAT signalingHeat shock protein 90 inhibition: rationale and clinical potential.Geldanamycin induces production of heat shock protein 70 and partially attenuates ototoxicity caused by gentamicin in the organ of Corti explantsPhase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumorsDevelopment and validation of a rapid and sensitive high-performance liquid chromatography-mass spectroscopy assay for determination of 17-(allylamino)-17-demethoxygeldanamycin and 17-(amino)-17-demethoxygeldanamycin in human plasmaSynthesis of reblastatin, autolytimycin, and non-benzoquinone analogues: potent inhibitors of heat shock protein 90.The synthesis and evaluation of flavone and isoflavone chimeras of novobiocin and derruboneGeldanamycin and Its Derivatives Inhibit the Growth of Myeloma Cells and Reduce the Expression of the MET Receptor.Identification of heat shock protein 90α as an IMH-2 epitope-associated protein and correlation of its mRNA overexpression with colorectal cancer metastasis and poor prognosis.Expression pattern of heat shock protein 90 gene of humphead snapper Lutjanus sanguineus during pathogenic Vibrio harveyi stress.17-DMAG targets the nuclear factor-kappaB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition.Destabilization of Bcr-Abl/Jak2 Network by a Jak2/Abl Kinase Inhibitor ON044580 Overcomes Drug Resistance in Blast Crisis Chronic Myelogenous Leukemia (CML)Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directionsCombined in silico and experimental approach for drug design: the binding mode of peptidic and non-peptidic inhibitors to hsp90 N-terminal domain.Redox regulation of the stability of the SUMO protease SENP3 via interactions with CHIP and Hsp90.Induction of nitric oxide synthase-dependent telomere shortening after functional inhibition of Hsp90 in human tumor cells.Histone deacetylase inhibitors: the epigenetic therapeutics that repress hypoxia-inducible factors.Noninvasive molecular imaging of cell death in myocardial infarction using 111In-GSAO.Luteolin induces carcinoma cell apoptosis through binding Hsp90 to suppress constitutive activation of STAT3.HSP90 inhibition downregulates thymidylate synthase and sensitizes colorectal cancer cell lines to the effect of 5FU-based chemotherapy.Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90.Combining targeted therapies: practical issues to consider at the bench and bedside.Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine.Current status of treatment of spinal and bulbar muscular atrophy.Hsp90 regulates O-linked β-N-acetylglucosamine transferase: a novel mechanism of modulation of protein O-linked β-N-acetylglucosamine modification in endothelial cells.Heat-shock protein 90 inhibitors as novel cancer chemotherapeutics - an update.Proteomic approaches for studying chemoresistance in cancer.Potential Prognostic Value of Histone Deacetylase 6 and Acetylated Heat-Shock Protein 90 in Early-Stage Breast CancerAnaplastic lymphoma kinase and its signalling molecules as novel targets in lymphoma therapy.Heat shock proteins and acute leukemias.HSP90 inhibitor 17-AAG selectively eradicates lymphoma stem cells.Geldanamycin induces apoptosis in human gastric carcinomas by affecting multiple oncogenic kinases that have synergic effects with TNF-related apoptosis-inducing ligand.
P2860
Q24298081-9A491A0D-07A9-4DFF-BB70-61C58B931373Q24301667-B5659C05-D025-4B1B-A250-54E55BAFF091Q24323029-F0034F37-7C07-4F7D-AAA1-C37055CD7A22Q24802251-66A76A66-977E-44AE-B36A-906DDA97F770Q25257535-713ECBE9-259D-4393-A81D-C304CDFFE209Q26860153-1C16D035-E704-4271-A211-A59A58F4B4F2Q28477468-B15C9427-925B-44C1-B76A-BF5405FCC02AQ28544030-4BA5415A-69B2-42C8-8831-B8DCF52F1C68Q28741023-BEA501B7-306B-4434-A448-F4267CE3DAA0Q30418761-01B72BEA-7E90-45DB-9CA2-CEFEAB9056D9Q30486570-A1F1F16C-9E57-41AC-95D7-B475A963FF9AQ33387877-BAE5ED13-7E41-407C-AF7A-118294E70719Q33440318-F95EEC61-5D8E-4475-B6DF-31766FFEC523Q33555574-49F62ACD-CBB6-4B8A-9D14-5F681749C18EQ33637496-C361FC3B-8667-49AD-8EF8-6EABD6000F67Q33789416-8AAED794-7677-42EA-B6E5-FDD3D543EE33Q33881899-80C196E3-669B-4763-BD88-418BD10B5B64Q33948624-F61D5EAF-029F-463E-AFAA-7BEA826F6F5DQ33997214-DD8A20C8-DAAE-47E7-8CD4-760922DC9CE1Q34082540-010B2F78-6CF6-4001-8B6D-BFA4810B45A0Q34164027-4A3220A5-D1CB-4268-8BE7-FAB2A7E8343EQ34192823-31210C50-BCF4-4624-B48E-D48B416DA72FQ34337304-A5FEF3B2-36FA-4E53-B989-CA5B090E8D82Q34353587-193439E4-11A2-4DD0-AE73-45D9199CE67BQ34382527-EE224669-1EE8-4D37-8EE2-1B20A30EE56CQ34417492-AEF397D1-7F4F-48FD-A8CC-D66AB956847DQ34474233-A0600C66-3979-4C5A-A85D-23706D785347Q34654819-8E504EA6-2B2F-4520-89C3-55EA92F9457BQ35127277-D47F53D2-58D5-43A7-9EEB-4E70F3E9D8E6Q35583672-E0C22516-3B29-4496-A5FA-612814CCAF7EQ35847836-4F469940-47C6-4D45-9A59-20DB509152C7Q36037644-CD5F2FCA-892A-4A95-B3D2-D0AFF91095CFQ36041929-59F422B4-78C4-4DBB-9304-4DF5FC198D83Q36066038-CBAAFFAB-5C23-4F70-A93E-7A03275A9393Q36126469-E159A3B9-0086-4DA6-A03C-A06D21744F51Q36145714-E6B46CCC-C118-44BC-AC3B-9ACCD46CE6F7Q36158713-4E87D286-9F1A-4151-8A11-005FAD941CBFQ36194587-1BAB360E-BD61-4ACB-8FF4-FC64D65BFF0EQ36237528-251AE398-907C-41FE-93A0-062D1074B63CQ36334890-D9B841B6-1A52-435F-847E-C000007A7B01
P2860
The Hsp90 chaperone complex as a novel target for cancer therapy.
description
2003 nî lūn-bûn
@nan
2003 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
The Hsp90 chaperone complex as a novel target for cancer therapy.
@ast
The Hsp90 chaperone complex as a novel target for cancer therapy.
@en
The Hsp90 chaperone complex as a novel target for cancer therapy.
@nl
type
label
The Hsp90 chaperone complex as a novel target for cancer therapy.
@ast
The Hsp90 chaperone complex as a novel target for cancer therapy.
@en
The Hsp90 chaperone complex as a novel target for cancer therapy.
@nl
prefLabel
The Hsp90 chaperone complex as a novel target for cancer therapy.
@ast
The Hsp90 chaperone complex as a novel target for cancer therapy.
@en
The Hsp90 chaperone complex as a novel target for cancer therapy.
@nl
P2093
P356
P1433
P1476
The Hsp90 chaperone complex as a novel target for cancer therapy.
@en
P2093
P304
P356
10.1093/ANNONC/MDG316
P577
2003-08-01T00:00:00Z